- Home
- BEAM vs KROS Comparison
BEAM vs KROS Comparison
Compare BEAM & KROS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BEAM
- KROS
- Stock Information
- Founded
- BEAM 2017
- KROS 2015
- Country
- BEAM United States
- KROS United States
- Employees
- BEAM N/A
- KROS N/A
- Industry
- BEAM Biotechnology: Biological Products (No Diagnostic Substances)
- KROS Biotechnology: Pharmaceutical Preparations
- Sector
- BEAM Health Care
- KROS Health Care
- Exchange
- BEAM Nasdaq
- KROS Nasdaq
- Market Cap
- BEAM 1.6B
- KROS 558.9M
- IPO Year
- BEAM 2020
- KROS 2020
- Fundamental
- Price
- BEAM $19.88
- KROS $13.41
- Analyst Decision
- BEAM Strong Buy
- KROS Buy
- Analyst Count
- BEAM 11
- KROS 13
- Target Price
- BEAM $48.90
- KROS $20.63
- AVG Volume (30 Days)
- BEAM 2.0M
- KROS 606.6K
- Earning Date
- BEAM 08-05-2025
- KROS 08-06-2025
- Dividend Yield
- BEAM N/A
- KROS N/A
- EPS Growth
- BEAM N/A
- KROS N/A
- EPS
- BEAM N/A
- KROS 0.11
- Revenue
- BEAM $63,578,000.00
- KROS $214,713,000.00
- Revenue This Year
- BEAM N/A
- KROS $5,006.76
- Revenue Next Year
- BEAM $8.82
- KROS N/A
- P/E Ratio
- BEAM N/A
- KROS $122.43
- Revenue Growth
- BEAM N/A
- KROS 91657.70
- 52 Week Low
- BEAM $13.53
- KROS $9.12
- 52 Week High
- BEAM $35.25
- KROS $72.37
- Technical
- Relative Strength Index (RSI)
- BEAM 67.72
- KROS 42.34
- Support Level
- BEAM $16.59
- KROS $13.25
- Resistance Level
- BEAM $17.38
- KROS $13.99
- Average True Range (ATR)
- BEAM 1.09
- KROS 0.39
- MACD
- BEAM 0.24
- KROS -0.06
- Stochastic Oscillator
- BEAM 93.78
- KROS 22.49
About BEAM Beam Therapeutics Inc.
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.
About KROS Keros Therapeutics Inc.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.